Found: 5
Select item for more details and to access through your institution.
Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 10, p. 1263, doi. 10.1080/0284186X.2022.2137693
- By:
- Publication type:
- Article
Limited-duration anti-PD-1 therapy for patients with metastatic melanoma.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 4, p. 438, doi. 10.1080/0284186X.2020.1716388
- By:
- Publication type:
- Article
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 3, p. 310, doi. 10.1080/0284186X.2019.1670862
- By:
- Publication type:
- Article
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 717, doi. 10.1007/s00262-020-02497-9
- By:
- Publication type:
- Article